Welcome to Multibagg AI
Log in to access personalized features
Home
Dashboard
Ask Iris
Discovery
Timeline
Multibagg AI is an AI powered stock research and analysis platform. We provide data, information, content, and analytics for publicly traded Indian companies listed on NSE and BSE. AI can make mistakes, check important information.
Prices might be delayed by a few minutes.
Join our Exclusive Community
Join our Exclusive Community
Made with 💙 in India. © Finsky Technologies Pvt Ltd. 2026
Get instant AI-powered insights about company performance, financials, and strategy. Ask questions about trends, competition, and developments while receiving responses backed by official documents and market data, with clear attribution to source documents.
Torrent Pharmaceuticals Limited is a key player in the Indian pharma sector, specializing in chronic and sub-chronic therapies like Cardiovascular and Central Nervous System.
The company recorded substantial growth with revenues of Rs. 3,302 crores and an operating EBITDA margin of 32.8% for Q2 FY'26.
India business growth was driven by cardiac and gastro therapies, while Brazil registered 21% growth, underscoring its strong international markets presence.
The US segment witnessed a 26% growth, benefitting from new launches and increased purchase volume of existing contracts.
Significant field force expansion and strategic product launches in India and Brazil suggest a focused approach on market penetration and growth.
Pharmaceuticals
Pharmaceuticals - Indian - Formulations
1,37,884 Cr
Low Risk
63.6
43.7
3.9
16.3
4,239.95
2,891.45
Sales CAGR
Profit CAGR
ROE
ROCE
Investor Presentation
Q3 FY26
Investor Presentation
Q2 FY26
Investor Presentation
Q1 FY26
Investor Presentation
Q4 FY25
Available on Pro Plan
Unlock reports, presentations, and AI-powered insights.
Investor Presentation
Q1 FY23
Available on Pro Plan
Unlock reports, presentations, and AI-powered insights.
Investor Presentation
Q4 FY18
Available on Pro Plan
Unlock reports, presentations, and AI-powered insights.
Investor Presentation
Q4 FY18
Available on Pro Plan
Unlock reports, presentations, and AI-powered insights.
Investor Presentation
Q3 FY18
Torrent Pharmaceuticals Ltd (TORNTPHARM) is currently trading at 4,074.05 per share. Stock prices fluctuate during market hours on NSE and BSE based on demand, company updates, and overall market conditions. Refer to the live price chart above for the most recent price movement.
Torrent Pharmaceuticals Limited is a key player in the Indian pharma sector, specializing in chronic and sub-chronic therapies like Cardiovascular and Central Nervous System. The company recorded substantial growth with revenues of Rs. 3,302 crores and an operating EBITDA margin of 32.8% for Q2 FY'26. India business growth was driven by cardiac and gastro therapies, while Brazil registered 21% growth, underscoring its strong international markets presence. The US segment witnessed a 26% growth, benefitting from new launches and increased purchase volume of existing contracts. Significant field force expansion and strategic product launches in India and Brazil suggest a focused approach on market penetration and growth.
Over the past 52 weeks, Torrent Pharmaceuticals Ltd has traded between a low of ₹2,891.45 and a high of ₹4,239.95. The 52-week high and low indicate the stock’s price range over the last year and help investors understand its volatility and recent trading levels.
Torrent Pharmaceuticals Ltd has a market capitalization of approximately 1,37,884.36. Market capitalization represents the total value of a company’s outstanding shares and helps investors understand its size, stability, and relative risk compared to other listed companies.
Torrent Pharmaceuticals Ltd’s investment profile depends on its business fundamentals, valuation, and long-term outlook. The stock currently trades at a PE ratio of 63.65 and operates in the Pharmaceuticals sector. Investors typically assess financial performance, growth prospects, and individual risk tolerance before making investment decisions.
Based on its market capitalization of 1,37,884.36 Cr, Torrent Pharmaceuticals Ltd is classified as a Large Cap stock. Large-cap stocks are generally more stable, while mid-cap and small-cap stocks tend to offer higher growth potential along with higher price volatility.
Torrent Pharmaceuticals Ltd operates in the Pharmaceuticals sector. Sector classification matters because companies in the same sector are often affected by similar economic conditions, regulatory changes, and competitive dynamics, which can influence overall stock performance.
The Price-to-Earnings (PE) ratio of Torrent Pharmaceuticals Ltd is 63.65. The PE ratio compares a company’s share price to its earnings and is commonly used to assess valuation. Comparing the PE ratio with sector peers and historical levels provides better context.
It is a ₹10,000 crore, five-year mission aimed at making India a global biopharmaceutical manufacturing hub by supporting domestic production of biologics, upgrading research institutes, and creating a large network of clinical trial sites.
Bearish
4
Neutral
7
Bullish
3
Bearish
4
Neutral
7
Bullish
35
Bearish
0
Neutral
0
Bullish
32
Discover detailed, AI-driven financial summaries that break down key metrics, trends, and insights—empowering you to make smarter investment decisions.
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
| Symbol | Price | Market Cap | P/E | P/B | Div Yield (%) | ROE (%) | ROCE (%) | ROA (%) |
4074.05 | 1,37,884 Cr | 63.65 | 16.32 | 0.15 | 25.33 | 27.37 | 14.64 | |
2913.00 | 36,468 Cr | 35.87 | 8.45 | 0.96 | 22.56 | 27.85 | 17.89 | |
1779.65 | 29,321 Cr | 33.93 | 3.07 | 1.01 | 8.27 | 12.46 | 7.18 | |
1414.65 | 19,596 Cr | 47.12 | 5.58 | 0.51 | 13.45 | 14.38 | 6.57 | |
915.95 | 19,340 Cr | 57.03 | 8.52 | 0.00 | 12.62 | 16.34 | 9.99 | |
1729.65 | 13,171 Cr | 21.42 | 4.17 | 0.35 | 18.64 | 23.29 | 17.76 | |
783.40 | 12,916 Cr | 62.57 | 11.25 | 0.00 | 26.49 | 22.49 | 11.57 |
Dividend & Financial Results
Torrent Pharmaceuticals' board approved standalone audited results and unaudited consolidated results for the quarter and nine months ended Dec 31, 2025, and declared an interim dividend of ₹29 (580%) per ₹5 share, payable on/around Mar 6, 2026.
Interim Dividend & Results
Torrent Pharmaceuticals' Board approved audited standalone Q3 and 9M FY2026 results and unaudited consolidated results, and declared an interim dividend of ₹29 per ₹5 share (580%), payable on/about 6 March 2026.
Dividend & Financials
Board approved audited standalone and unaudited consolidated results for quarter & nine months ended Dec 31, 2025, received unqualified auditor report, and declared an interim dividend of ₹29 per ₹5 share (580%), payable ~6 Mar 2026.
Dividend Announcement
Board approved audited standalone and unaudited consolidated results for quarter and nine months ended 31 Dec 2025 and declared an interim dividend of ₹29 per ₹5 share (580%), payable on/around 6 Mar 2026; auditor report unqualified.
Investor Presentation
Investor presentation of unaudited consolidated results for quarter and nine months ended 31 Dec 2025; Q3 revenue Rs 3,303 crore (+18% YoY) and 9M revenue Rs 9,783 crore (+14% YoY), with broad-based geographic growth.
Financial Results & Dividend
Board approved audited standalone and unaudited consolidated results for quarter and nine months ended 31 Dec 2025 and declared an interim dividend of ₹29 per ₹5 share (580%), payable ~6 Mar 2026.
